Wikipedia -WSS

Wikipedia

author：explore 2025-09-30 12:18:41 - browse：863

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： What will save rural psychiatry services? Higher Medicaid payments

Wikipedia

WSS

Insmed lung disease drug hits target in key Phase 3 trial

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Federal judge rules Oregon’s tough new gun law is constitutional

Can CDC director Mandy Cohen drive consensus in Washington?

David Sabatini, ex

focus

Wikipedia

knowledge

Medicare details structure of new drug price negotiation program

Insmed lung disease drug hits target in key Phase 3 trial

Medical records are filled with copy

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Apple is now the first public company to be valued at $3 trillion

J&J expands global access to TB drug amid advocacy campaign

What does generative AI mean for health care? We asked experts

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Bright Health sells Medicare Advantage business to Molina

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

leisure time

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Does aspartame cause cancer? What new WHO guidance says

Biohaven protein

Report: NIH

Childbirth

hotspot

knowledge

Wikipedia

entertainment